Press Releases

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Sep 03, 2021

AVROBIO to Participate at Four Upcoming Investor Conferences

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming

Sep 01, 2021

AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update

U.S. Food and Drug Administration granted Fast Track Designation to AVR-RD-04 for cystinosis Company is planning to initiate multiple registration trials in 2022 Multiple data and regulatory updates anticipated over next 12 months CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2021-- AVROBIO, Inc .

Aug 05, 2021

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Aug 04, 2021

AVROBIO to Present at Two Upcoming Investor Conferences in August

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming

Aug 02, 2021

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Jul 08, 2021

AVROBIO to Present at the JMP Securities Life Sciences Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 10, 2021-- AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present at the JMP Securities Life

Jun 10, 2021

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to an

Jun 04, 2021

AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update

Held meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for AVR-RD-01 for Fabry disease Dosing completion in ongoing FAB-GT Phase 2 trial reaches 50%, with three additional patients dosed in three months CAMBRIDGE, Mass.

May 13, 2021

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

May 06, 2021



Displaying 1 - 10 of 24

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.